Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 235-238

  Bruzzese, Vincenzo ^a,b   Pepe, J ^a  

^a Area of Internal Medicine and Immunology   (Italy)

^b NONE   (Italy)

Author keywords

Anti TNF ; Cyclosporine; Erythrodermic psoriasis; IFN

Indexed keywords

CORTISONE; CYCLOSPORIN A; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BACKACHE; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 62649173216     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200126     Document Type: Article

References (11)

1. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesion during anti-TNF Therapy: A Review. Semin Arthritis Rheum 2008; 37(4):251-5.
2. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007; 34(2):380-5.
3. Sfikasis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy. A paradoxical adverse reaction. Arthritis Rheum 2005; 8:2513-18.
4. Ritchlin C, Tausk F. A medical conundrum: onset of psoriasis in patients receiving antitumor necrosis factor agents. Ann Rheum Dis 2006; 65:1541-44.
5. Dutz JP. Tumor necrosis factor-Alfa inhibition and palmoplantaris pustolosis: Janus-faced therapy? J Rheumatol 2007; 34:247-9.
6. Bruzzese V. Psoriasi suberitrodermica diffusa indotta da Infliximab. Reumatismo 2007; 59(4):328-331.
7. Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology 2005; 44:172-5.
8. Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol 2005; 125:xiv-xv.
9. Bancherau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004; 20:539-50.
10. Palucka AK, Black JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmume diseases, Proc Natl Acad Sci USA 2005; 102:3372-7.
11. Nestle FO, Conrad C, Tun-Kyj A, et al. Plasmocytoid predendritic cells initiate psoriasis through interferon-alfa production. J Exp Med 2005; 202: